By Michael Susin
Fusion Antibodies said that it has signed an agreement with an unnamed U.S.-based artificial intelligence and machine learning company to support its new service for antibodies screening.
The U.K.-based biotechnology group said that both parties will co-market the combined service offerings and each one will be entitled to a fee for any new business introduced to the other.
The company said that the offer will cover both the design of antibodies and their production and evaluation in vitro, significantly improving success rates, output affinities while reducing costs.
Shares at 0720 GMT were up 0.5 pence, or 7.4%, at 7.25 pence.
Write to Michael Susin at [email protected]
Read the full article here
